RT Journal Article
SR Electronic
T1 COVID-19: impact of original, Gamma, Delta, and Omicron variants of SARS-CoV-2 in vaccinated and unvaccinated pregnant and postpartum women
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.05.22280754
DO 10.1101/2022.10.05.22280754
A1 Serra, Fabiano Elisei
A1 Rosa, Elias Ribeiro
A1 de Rossi, Patricia
A1 Vieira Francisco, Rossana Pulcineli
A1 Rodrigues, Agatha Sacramento
YR 2022
UL http://medrxiv.org/content/early/2022/10/07/2022.10.05.22280754.abstract
AB Introduction This study compares the clinical characteristics and disease progression of vaccinated and unvaccinated pregnant and postpartum women positive for the original, Gamma, Delta, and Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using Brazilian epidemiological data.Methods Data of pregnant or postpartum patients with coronavirus disease 2019 (COVID-19) SARS-CoV-2 confirmed using polymerase chain reaction from February 2020 to July 2022 were extracted from a Brazilian national database. The patients were divided based on vaccination status and viral variant (original, Gamma, Delta, and Omicron). The patients’ demographic data, clinical characteristics, comorbidities, signs, symptoms, and outcomes were retrospectively compared.Results Data from 10,003 pregnant and 2,361 postpartum women were extracted from the database. Among unvaccinated patients, postpartum women were more likely to be admitted to the intensive care unit (ICU). These patients were more likely to require invasive ventilation when infected with the original, Gamma, and Omicron variants and were more likely to die when infected with the original and Gamma variants. Patients who were vaccinated had reduced adverse outcomes including ICU admission, requirement for invasive ventilation, and death.Conclusion Postpartum women were more likely to develop severe COVID-19 that required ICU admission or invasive ventilatory support or led to death, among all variants, especially when the patients were unvaccinated. Therefore, the risk of severe COVID-19 should not be underestimated after delivery. Vaccinated patients had a lower risk of severe outcomes. Vaccination should be a top priority in pregnant and postpartum patients.WHAT IS ALREADY KNOWN ON THIS TOPIC The obstetric population has a higher risk of adverse outcomes due to coronavirus disease 2019 (COVID-19). Few studies have compared the outcomes of pregnant and postpartum patients or vaccinated and unvaccinated patients; however, no studies have separately investigated the effects of each viral variant.WHAT THIS STUDY ADDS Postpartum women are more likely to have adverse outcomes, including the requirements for intensive care and invasive ventilation and death, compared with pregnant women. Vaccinated women had fewer adverse outcomes. The viral variants did not significantly affect the outcomes of these patients.HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY The risks of COVID-19 infection should not be underestimated in postpartum women. Postpartum women infected with COVID-19, especially those who are not vaccinated, should be monitored carefully. Vaccination should be a top priority in pregnant and postpartum women.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-027961]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. This work is also funded by CNPq (Award Number: 445881/2020-8) and FAPES (Award Number: 44437.699.40413.22122020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://opendatasus.saude.gov.br/dataset/srag-2020 and https://opendatasus.saude.gov.br/dataset/srag-2021-e-2022I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available in GitHub repository at https://github.com/observatorioobstetrico/COVID-19-impact-of-original-Gamma-Delta-and-Omicron-variants-of-SARS-CoV-2-in-vaccinated-and-unv. These data were derived from the following resources available in the public domain: https://opendatasus.saude.gov.br/dataset/srag-2020 and https://opendatasus.saude.gov.br/dataset/srag-2021-e-2022 obtained on 25 July 2022. https://github.com/observatorioobstetrico/COVID-19-impact-of-original-Gamma-Delta-and-Omicron-variants-of-SARS-CoV-2-in-vaccinated-and-unv